Breaking News, Collaborations & Alliances

Therapix in Oral Anti-CD3 Development Pact in China

Will develop antibody for the treatment of a variety of inflammatory diseases

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Therapix Bio’s subsidiary, OrImmune Bio Ltd., has entered a strategic collaboration with Nanjing BioSciKin Co. to develop, manufacture and commercialize the company’s Anti-CD3 antibody in the Chinese market (China, Taiwan, Hong Kong and Macau). The Anti-CD3 antibody is an orally-administered antibody for the treatment of a variety of inflammatory diseases such as Non Alcoholic Steato Hepatitis (fatty liver disease).   The companies are working toward an agreement that would provide Nanjing...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters